Dare Bioscience
DARE
27 hedge funds and large institutions have $2.75M invested in Dare Bioscience in 2026 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 5 closing their positions.
175% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 4
47% more capital invested
Capital invested by funds: $1.87M → $2.75M (+$882K)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
8% more funds holding
Funds holding: 25 → 27 (+2)
1.65% more ownership
Funds ownership: 7.04% → 8.69% (+1.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$399K |
| 2 |
BlackRock
New York
|
+$106K |
| 3 |
Jane Street
New York
|
+$80.7K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
+$66.1K |
| 5 |
Vanguard Fiduciary Trust
Malvern,
Pennsylvania
|
+$56.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$84.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$81.7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$40.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$31.2K |
| 5 |
Two Sigma Investments
New York
|
-$24.2K |
DARE Hedge Fund Activity: Q2 2026 in Review
27 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Dare Bioscience (DARE) for Q2 2026, worth a combined $2.75M — up 47% from $1.87M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new DARE positions and 5 closed out — a net gain of 2 holders — while 11 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Capital Management, adding an estimated $399K. The largest seller was Geode Capital Management, cutting an estimated $84.4K.
- 27 institutional investors held Dare Bioscience (DARE) as of Q2 2026, up from 25 in Q1 2026.
- Funds reported $2.75M of Dare Bioscience stock for Q2 2026, up 47% quarter-over-quarter.
- 7 funds opened new Dare Bioscience positions in Q2 2026 and 5 closed out, a net change of +2 holders.
- The largest Dare Bioscience buyer in Q2 2026 was Vanguard Capital Management, an estimated $399K added.
- The largest Dare Bioscience seller in Q2 2026 was Geode Capital Management, an estimated $84.4K sold.
Based on aggregated 13F filings for Q2 2026.